Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Congenital Abnormalities 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 114Temozolomide 104Bevacizumab 71Radiotherapy 67Magnetic Resonance Spectroscopy 67Carboplatin 29pembrolizumab 28Irinotecan 26Surgical Procedures, Operative 25Radiation 23Nivolumab 23Etoposide 22Magnetic Resonance Imaging 21Ipilimumab 21Erlotinib Hydrochloride 21Cyclophosphamide 21Surveys and Questionnaires 19Aminolevulinic Acid 18Specimen Handling 16Pemetrexed 16Mental Status and Dementia Tests 16Cisplatin 16Carmustine 15Topotecan 14Trastuzumab 13Saline Solution 12Neuropsychological Tests 12Gefitinib 11Filgrastim 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Brain Neoplasms × trebananib × Clear all
NCT01290263 2017-07-02

Amgen 386 for Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
48 enrolled 13 charts
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡